{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.177","meta":{"versionId":"6","lastUpdated":"2021-03-19T01:00:22.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177","version":"20210319","name":"Immunotherapy Administration","status":"active","date":"2021-03-19T01:00:22-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2022","concept":[{"code":"Q2041","display":"Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"},{"code":"Q2042","display":"Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"}]}]}}